On the other hand, if India received a lower allocation of 95-125 million doses, then the cost to the government of procuring additional shots would go up to $1.8 billion.
On the other hand, some participants said they had felt pain at the injection site, which resolved in a few days. That phase of vaccination will begin late summer or early fall.
Its objective is to ensure that people obtain global access to Covid-19 vaccines, irrespective of their wealth.
The European Medicines Agency (EMA) is set to approve its first COVID-19 vaccine on December 23, a German government source told Reuters on Tuesday, putting EU countries on track to start to catch up with the United States and Britain, where immunisation campaigns are underway.
"Albertans can be confident that this vaccine is safe and that it will be administered efficiently without compromising quality", says Wynnyk. That's why vaccine recipients are supposed to be observed after getting the shot, in case they need immediate treatment.
India, which has the world's second highest caseload of coronavirus behind the United States, plans to inoculate 300 million people over the next six to eight months, likely with vaccines from AstraZeneca, Russia's Sputnik, Zydus Cadila and India's own Bharat Biotech.
Another 2 million doses of the Pfizer vaccine and 5.9 million doses of the Moderna vaccine could be allocated next week, Health Secretary Alex Azar said on a conference call on Wednesday. "COVAXIN has been created to be efficacious when subjects receive both the doses".
Bharat Biotech further informed that the Phase-III trials are double-blinded and randomised, where 50 per cent of the subjects will receive the vaccine and 50 per cent will receive a placebo.
Overall, the trial found no serious safety issues, but regulators and the company are continuing to monitor for adverse events after vaccination. People receiving the vaccine will require two doses, about one month apart, for it to be effective.
The COVAXIN is being developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).